Roche Palo Alto LLC

Hoffmann-La Roche Inc.

Syntex (u.s.a.) Inc.

F. Hoffmann-La Roche Ag

Clara Jeou Jen Lin

Michael Patrick Dillon

Matthew C Lucas

Alam Jahangir

Yansheng Zhai

Ronald Charles Hawley

Counde O'Yang

Francisco Xavier Talamas

Robert James Weikert

Sharada Shenvi Labadie

Ryan Craig Schoenfeld

Chris Allen Broka

David Scott Carter

Amy Geraldine Moore

Daniel Warren Parish

Xiaoming Zhang

Shaoqing Chen

Johannes Cornelius Hermann

Stephen Matthew Lynch

Ann Marie Madera

Andreas Kuglstatter

Nidhi Arora

Jutta Wanner

Pravin Iyer

Kerem Erol Ozboya

Eva Papp

Robin D Clark

Hans Maag

David Bruce Repke

Ralph New Harris, Iii

Christine E Brotherton-Pleiss

Joan Marie Caroon

Marzia Villa

Shelley K Gleason

Sharathchandra Surendra Hegde

Stephen M Lynch

Compounds of the formula I or II: wherein X, m, Ar, Rand Rare as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof,wherein D, X, Y, R, R, R, R, R, R, Rand Rare as defined herein.

[object Object]

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof,

Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof

Compounds of the formula: or pharmaceutically acceptable salts thereof,wherein m, n, Ar, R, R, Rand Rare defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Pyrrolidinyl and piperidinyl ketone derivatives and uses thereof

Compounds having the formula I wherein R, R, R, R, Rand X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

Heterocyclic antiviral compounds

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the compounds being of formula (I): wherein D, X, R, R, R, R, R, R, Rand Rare as defined herein.

Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genitourinary, gastrointestinal, and respiratory disorders: wherein

Compounds of the Formula: where R-Rare those defined herein and methods for producing the same. Also provided are pharmaceutical compositions comprising a Compound of Formula I and methods for their use as therapeutic agents.

Imidazolinylmethyl aralkylsulfonamides

This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I:wherein m, A, X, Y, R, R, R, Rand Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Method for detecting a gram-negative bacterial autoinducer molecule

Imidazolinyimethyl aralklsulfonamides

This invention relates to muscarinic receptor antagonist compounds selected from the group of compounds represented by Formula I:

2-arylethyl-(piperidin-4-ylmethyl)amine derivatives

Growing community of inventors

Palo Alto, CA, United States of America

Clara Jeou Jen Lin